Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
30.3M
-
Number of holders
-
146
-
Total 13F shares, excl. options
-
35.3M
-
Shares change
-
-582K
-
Total reported value, excl. options
-
$558M
-
Value change
-
-$6.43M
-
Put/Call ratio
-
0.57
-
Number of buys
-
79
-
Number of sells
-
-52
-
Price
-
$15.82
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q3 2025
166 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2025.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 146 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.3M shares
.
Largest 10 shareholders include ADAR1 Capital Management, LLC (5.39M shares), VANGUARD GROUP INC (2.72M shares), BlackRock, Inc. (2.72M shares), Madison Avenue Partners, LP (2.71M shares), Western Standard LLC (2.19M shares), TANG CAPITAL MANAGEMENT LLC (1.42M shares), D. E. Shaw & Co., Inc. (1.33M shares), GOLDMAN SACHS GROUP INC (1.33M shares), STATE STREET CORP (1.3M shares), and Nantahala Capital Management, LLC (1.23M shares).
This table shows the top 146 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.